RAHWAY, N. J.--(BUSINESS WIRE)--CFM, IMM and NXTsoft, the leading provider of API connectivity, document workflow, teller workflow, and data analytics software, today announced 55 new financial ...
IMM-1-104 combined with mGnP shows promising efficacy and tolerability in first-line pancreatic cancer, with a 43% ORR and 86% DCR among seven patients. IMM-1-104 demonstrated target lesion shrinkage ...
Combining “complementary” audio technology could speed the adoption of the immersive Atmos sound format, a Dolby exec says. By Carolyn Giardina Tech Editor Dolby Laboratories has acquired rival ...
IND 32095 is Immuron’s Investigational new drug (IND) application for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) and is now ...
- IMM-1-104 Fast Track designation now granted for the treatment of both first and second-line pancreatic ductal adenocarcinoma (PDAC); provides potential to accelerate IMM-1-104’s path to U.S. FDA ...
Immuron to develop U.S. registration dossier for IMM-124E for Travelers' Diarrhea Company anticipates significant inflection in sales with successful FDA registration of IMM-124E Company to pursue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results